Regorafinib escalation for colorectal cancer

Not Applicable

Recruiting

• Conditions: metastatic colorectal cancer

• Registration Number: JPRN-UMIN000028933
• Lead Sponsor: Department of Coloproctological Surgery, Juntendo University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-10-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 55

Inclusion Criteria

Not provided

Exclusion Criteria

1)contraindications for Regorafinib 2)previously received chemotherapy with Regorafinib 3)severe drug allergy 4)pregnant woman or Possibility of the pregnant woman. male patient who hoping partner's pregnancy. 5)patient who has severe clinical complications (symptomatic unstable ischemic heart disease, arrhythmia, acute myocardial infarction within 6 months, liver cirrhosis, renal failure, active gastrointestinal ulcer, ileus, uncontrolled diabetes, uncontrolled hypertension, etc.) 6)other active malignancies 7)severe disorder of liver function 8)Uncontrollable hypertension 9)Severe complication 10)Synchronous or metachronous multiple malignancy within the last 5 year disease free interval 11)Under continuous steroid administration 12)decision of unsuitable for this study by the investigator

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
progression free survival